USANA Health Sciences, Inc.(USNA)Earnings, Financials & Key Ratios

USNA•NYSE

$20.01

$369M mkt cap·34.5× P/E·Price updated May 6, 2026

SectorConsumer Defensive IndustryPackaged Foods Sub-IndustryNutrition and functional foods

AboutUSANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine for research in the field of traditional Chinese medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.Show more

Revenue$925M+8.3%
EBITDA$91M+2.3%
Net Income$11M-74.4%
EPS (Diluted)0.58-73.5%
Gross Margin78.29%-1.4%
EBITDA Margin9.79%-5.5%
Operating Margin5.5%-29.2%
Net Margin1.16%-76.4%
ROE1.84%-76.3%
ROIC8.61%-46.0%
Debt/Equity0.02-64.3%
Interest Coverage50.32-81.5%

Technical→

USNA Key Insights

USANA Health Sciences, Inc. (USNA) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Company is almost debt free
✓Strong Piotroski F-Score: 7/9
✓High quality earnings: Operating CF exceeds net income
✓Share count reduced 3.1% through buybacks
✓Trading at only 0.6x book value
✓Efficient asset utilization: 1.2x turnover

✗Weaknesses

✗Profits declining 38.7% over 5 years
✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

USNA Price & Volume

USANA Health Sciences, Inc. (USNA) stock price & volume — 10-year historical chart

Loading chart...

USNA Growth Metrics

USANA Health Sciences, Inc. (USNA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years0.07%

5 Years-4%

3 Years-2.51%

TTM8.28%

Profit CAGR

10 Years-19.54%

5 Years-38.73%

3 Years-46.27%

TTM-74.42%

EPS CAGR

10 Years-16.66%

5 Years-37.03%

3 Years-45.54%

TTM-74.75%

Return on Capital

10 Years31.07%

5 Years20.48%

3 Years13.13%

Last Year8.32%

USNA Recent Earnings

USANA Health Sciences, Inc. (USNA) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 9/12 qtrs (75%)●Beat Revenue 8/12 qtrs (67%)

Q2 2026Latest

May 5, 2026

EPS

$0.61

Est $0.44

+38.6%

Revenue

$250M

Est $241M

+3.7%

Q1 2026

Feb 17, 2026

EPS

$0.60

Est $0.41

+46.3%

Revenue

$226M

Est $226M

+0.1%

Q4 2025

Oct 21, 2025

EPS

$0.15

Est $0.25

-160.0%

Revenue

$214M

Est $220M

-2.8%

Q3 2025

Jul 22, 2025

EPS

$0.74

Est $0.54

+37.0%

Revenue

$236M

Est $226M

+4.4%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 5, 2026	$0.61vs $0.44+38.6%	$250Mvs $241M+3.7%
Q1 2026	Feb 17, 2026	$0.60vs $0.41+46.3%	$226Mvs $226M+0.1%
Q4 2025	Oct 21, 2025	$0.15vs $0.25-160.0%	$214Mvs $220M-2.8%
Q3 2025	Jul 22, 2025	$0.74vs $0.54+37.0%	$236Mvs $226M+4.4%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
NUSNu Skin Enterprises, Inc.Direct Competitor	353.79M	7.34	2.31	-14.26%	7.02%	13.7%	0.35
NATRNature's Sunshine Products, Inc.Direct Competitor	459.31M	26.24	24.75	5.67%	4.07%	11.85%	0.12
NHTCNatural Health Trends Corp.Direct Competitor	34.6M	3.10	-40.42	-7.42%	-3.03%	-4.88%	0.13
HLFHerbalife Nutrition Ltd.Product Competitor	1.7B	16.44	7.47	0.89%	4.67%
PLBYPlayboy, Inc.Product Competitor	189.54M	1.68	-12.92	4.13%	-10.48%	-247.79%	1.30
ATGEAdtalem Global Education Inc.Product Competitor	3.7B	106.64	17.57	12.85%	13.41%	18.37%	0.54
MGPIMGP Ingredients, Inc.Product Competitor	412.89M	19.32	-3.87	-23.77%	-45.97%	-32.05%	0.37
VITLVital Farms, Inc.Product Competitor	537.57M	12.00	8.33	25.26%	8.73%	18.87%	0.15

Compare USNA vs Peers

USANA Health Sciences, Inc. (USNA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NUS

Most directly comparable listed peer for USNA.

Scale Benchmark

vs AMZN

Larger-name benchmark to compare USNA against a more recognizable public peer.

Peer Set

Compare Top 5

vs NUS, NATR, NHTC, HLF

USNA Income Statement

USANA Health Sciences, Inc. (USNA) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Jan'26
Sales/Revenue	1.05B	1.19B	1.06B	1.13B	1.19B	998.6M	921.01M	854.5M	925.26M
Revenue Growth %	4.09%	13.56%	-10.79%	6.95%	4.57%	-15.83%	-7.77%	-7.22%	8.28%
Cost of Goods Sold	195.36M	217.44M	202.03M	222.86M	230.93M	207.28M	189.4M	175.75M	200.85M
COGS % of Revenue	18.65%	18.28%	19.04%	19.64%	19.46%	20.76%	20.56%	20.57%	21.71%
Gross Profit	851.9M▲ 0%	971.81M▲ 14.1%	858.87M▼ 11.6%	911.79M▲ 6.2%	955.53M▲ 4.8%	791.32M▼ 17.2%	731.62M▼ 7.5%	678.75M▼ 7.2%	724.4M▲ 6.7%
Gross Margin %	81.35%	81.72%	80.96%	80.36%	80.54%	79.24%	79.44%	79.43%	78.29%
Gross Profit Growth %	4.86%	14.08%	-11.62%	6.16%	4.8%	-17.19%	-7.54%	-7.23%	6.73%
Operating Expenses	719.4M	783.46M	712.68M	735.29M	785.34M	683.7M	638.54M	612.43M	673.54M
OpEx % of Revenue	68.69%	65.88%	67.18%	64.8%	66.19%	68.47%	69.33%	71.67%	72.8%
Selling, General & Admin	710.45M	773.22M	702.42M	724.66M	774.23M	672.14M	627.1M	600.86M	337.37M
SG&A % of Revenue	67.84%	65.02%	66.21%	63.87%	65.25%	67.31%	68.09%	70.32%	36.46%
Research & Development	8.95M	10.24M	10.26M	10.63M	11.11M	11.56M	11.45M	11.57M	0
R&D % of Revenue	0.85%	0.86%	0.97%	0.94%	0.94%	1.16%	1.24%	1.35%	-
Other Operating Expenses	0	0	0	0	0	0	0	0	336.17M
Operating Income	132.5M▲ 0%	188.35M▲ 42.1%	146.19M▼ 22.4%	176.49M▲ 20.7%	170.19M▼ 3.6%	107.61M▼ 36.8%	93.07M▼ 13.5%	66.32M▼ 28.7%	50.86M▼ 23.3%
Operating Margin %	12.65%	15.84%	13.78%	15.55%	14.34%	10.78%	10.11%	7.76%	5.5%
Operating Income Growth %	-4.41%	42.15%	-22.39%	20.73%	-3.57%	-36.77%	-13.51%	-28.74%	-23.31%
EBITDA	148.46M	205.08M	168.98M	199M	192.38M	129.02M	113.47M	88.55M	90.56M
EBITDA Margin %	14.18%	17.24%	15.93%	17.54%	16.21%	12.92%	12.32%	10.36%	9.79%
EBITDA Growth %	-2.39%	38.13%	-17.6%	17.76%	-3.32%	-32.93%	-12.06%	-21.96%	2.27%
D&A (Non-Cash Add-back)	15.96M	16.73M	22.79M	22.51M	22.19M	21.41M	20.39M	22.23M	39.7M
EBIT	134.69M	191.55M	146.19M	178.46M	170.7M	108.81M	102.72M	76.63M	42.37M
Net Interest Income	2.14M	4.39M	4.64M	2.03M	2.46M	3.6M	9.38M	11.04M	1.57M
Interest Income	2.19M	4.43M	4.71M	2.54M	2.52M	3.79M	9.64M	11.32M	2.42M
Interest Expense	46K	36K	66K	507K	57K	192K	262K	281K	842K
Other Income/Expense	2.14M	3.16M	4.31M	1.46M	450K	1.01M	9.38M	10.03M	-9.34M
Pretax Income	134.64M▲ 0%	191.51M▲ 42.2%	150.5M▼ 21.4%	177.95M▲ 18.2%	170.64M▼ 4.1%	108.62M▼ 36.3%	102.45M▼ 5.7%	76.35M▼ 25.5%	41.53M▼ 45.6%
Pretax Margin %	12.86%	16.1%	14.19%	15.68%	14.38%	10.88%	11.12%	8.94%	4.49%
Income Tax	72.11M	65.29M	49.97M	53.28M	54.14M	39.27M	38.66M	34.29M	30.05M
Effective Tax Rate %	53.55%	34.09%	33.2%	29.94%	31.73%	36.15%	37.74%	44.91%	72.36%
Net Income	62.53M▲ 0%	126.22M▲ 101.8%	100.53M▼ 20.4%	124.66M▲ 24.0%	116.5M▼ 6.5%	69.35M▼ 40.5%	63.79M▼ 8.0%	42.03M▼ 34.1%	10.76M▼ 74.4%
Net Margin %	5.97%	10.61%	9.48%	10.99%	9.82%	6.94%	6.93%	4.92%	1.16%
Net Income Growth %	-37.49%	101.85%	-20.36%	24.01%	-6.54%	-40.47%	-8.02%	-34.11%	-74.4%
Net Income (Continuing)	62.53M	126.22M	100.53M	124.66M	116.5M	69.35M	63.79M	42.06M	11.48M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	54.22M	53.17M
EPS (Diluted)	2.53▲ 0%	5.12▲ 102.4%	4.41▼ 13.9%	5.86▲ 32.9%	5.73▼ 2.2%	3.59▼ 37.3%	3.30▼ 8.1%	2.19▼ 33.6%	0.58▼ 73.5%
EPS Growth %	-36.59%	102.37%	-13.87%	32.88%	-2.22%	-37.35%	-8.08%	-33.64%	-73.52%
EPS (Basic)	2.60	5.36	4.44	5.89	5.78	3.60	3.33	2.20	0.58
Diluted Shares Outstanding	24.71M	24.64M	22.82M	21.26M	20.34M	19.31M	19.34M	19.16M	18.57M
Basic Shares Outstanding	24.02M	23.57M	22.64M	21.04M	20.15M	19.25M	19.25M	19.06M	18.57M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

USNA Balance Sheet

USANA Health Sciences, Inc. (USNA) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Jan'26
Total Current Assets	340.16M	392.33M	327.61M	423.21M	362.85M	381.23M	417.75M	279.19M	288.4M
Cash & Short-Term Investments	247.13M	277.87M	234.83M	312.88M	239.83M	288.42M	330.42M	181.77M	158.38M
Cash Only	247.13M	214.33M	234.83M	312.88M	239.83M	288.42M	330.42M	181.77M	158.38M
Short-Term Investments	0	63.54M	0	0	0	0	0	0	0
Accounts Receivable	13.46M	14.03M	8.76M	7.42M	7.16M	7.21M	7.2M	8.22M	0
Days Sales Outstanding	4.69	4.31	3.01	2.39	2.2	2.64	2.85	3.51	-
Inventory	62.92M	81.95M	68.91M	90.22M	98.32M	67.09M	61.45M	69.73M	102.61M
Days Inventory Outstanding	117.55	137.56	124.49	147.77	155.4	118.14	118.43	144.83	186.47
Other Current Assets	8.34M	9.2M	4.95M	4.01M	3.68M	7.12M	7.28M	5.7M	27.42M
Total Non-Current Assets	179.11M	162.13M	189.33M	217.68M	214.89M	215.32M	215.01M	469.01M	454.51M
Property, Plant & Equipment	102.85M	92.03M	126.5M	128.39M	125.57M	117.77M	99.81M	94.56M	94.38M
Fixed Asset Turnover	10.18x	12.92x	8.39x	8.84x	9.45x	8.48x	9.23x	9.04x	9.80x
Goodwill	17.42M	16.82M	16.64M	17.37M	17.67M	17.37M	17.1M	144.17M	137.96M
Intangible Assets	35.15M	31.81M	29.84M	30.8M	30.44M	32.43M	29.92M	151.82M	133.15M
Long-Term Investments	9.81M	2.91M	2.86M	3.06M	23.82M	2.9M	2.83M	2.74M	0
Other Non-Current Assets	11.02M	15.22M	10.41M	33.42M	12.55M	35.05M	52.07M	56.07M	61.8M
Total Assets	519.27M▲ 0%	554.46M▲ 6.8%	516.93M▼ 6.8%	640.89M▲ 24.0%	577.74M▼ 9.9%	596.55M▲ 3.3%	632.76M▲ 6.1%	748.19M▲ 18.2%	742.91M▼ 0.7%
Asset Turnover	2.02x	2.14x	2.05x	1.77x	2.05x	1.67x	1.46x	1.14x	1.25x
Asset Growth %	10.33%	6.78%	-6.77%	23.98%	-9.85%	3.26%	6.07%	18.24%	-0.71%
Total Current Liabilities	141.18M	148.69M	136.1M	168.07M	160.79M	143.83M	118.84M	139.63M	128.56M
Accounts Payable	11.79M	9.95M	12.53M	18.2M	13.51M	11.05M	10.07M	11.98M	17.26M
Days Payables Outstanding	22.02	16.7	22.63	29.8	21.35	19.46	19.41	24.89	31.37
Short-Term Debt	0	0	8.32M	8.62M	7.08M	6.89M	786K	23M	14M
Deferred Revenue (Current)	17M	15.05M	13.85M	15.95M	19.64M	20.88M	13.91M	12.05M	0
Other Current Liabilities	28.71M	35.69M	68.96M	85.36M	83.01M	82.71M	73.75M	-4.75M	97.3M
Current Ratio	2.41x	2.64x	2.41x	2.52x	2.26x	2.65x	3.52x	2.00x	2.24x
Quick Ratio	1.96x	2.09x	1.90x	1.98x	1.65x	2.18x	3.00x	1.50x	1.45x
Cash Conversion Cycle	100.22	125.17	104.87	120.36	136.25	101.32	101.88	123.45	-
Total Non-Current Liabilities	14.88M	14.63M	29.12M	31.16M	21.83M	18.24M	16.71M	22.24M	28.08M
Long-Term Debt	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	17.27M	12.86M	10.21M	6.89M	5.14M	10.19M	0
Deferred Tax Liabilities	13.73M	13.37M	10.28M	12.01M	7.5M	4.07M	4.55M	4.07M	4.89M
Other Non-Current Liabilities	1.15M	1.26M	1.57M	6.3M	4.11M	7.28M	7.02M	7.97M	23.19M
Total Liabilities	156.06M	163.32M	165.22M	199.24M	182.62M	162.08M	135.56M	161.86M	156.64M
Total Debt	0	0	25.6M	21.47M	17.3M	13.78M	13.21M	39.2M	14M
Net Debt	-247.13M	-214.33M	-209.23M	-291.4M	-222.54M	-274.64M	-317.21M	-142.56M	-144.38M
Debt / Equity	-	-	0.07x	0.05x	0.04x	0.03x	0.03x	0.07x	0.02x
Debt / EBITDA	-	-	0.15x	0.11x	0.09x	0.11x	0.12x	0.44x	0.15x
Net Debt / EBITDA	-1.66x	-1.05x	-1.24x	-1.46x	-1.16x	-2.13x	-2.80x	-1.61x	-1.59x
Interest Coverage	2927.96x	5320.72x	2215.00x	351.98x	2994.72x	566.73x	392.04x	272.71x	50.32x
Total Equity	363.21M▲ 0%	391.15M▲ 7.7%	351.71M▼ 10.1%	441.65M▲ 25.6%	395.12M▼ 10.5%	434.47M▲ 10.0%	497.2M▲ 14.4%	586.33M▲ 17.9%	586.27M▼ 0.0%
Equity Growth %	11.66%	7.69%	-10.08%	25.57%	-10.53%	9.96%	14.44%	17.93%	-0.01%
Book Value per Share	14.70	15.87	15.41	20.78	19.42	22.50	25.70	30.60	31.56
Total Shareholders' Equity	363.21M	391.15M	351.71M	441.65M	395.12M	434.47M	497.2M	532.11M	533.1M
Common Stock	24K	24K	22K	21K	19K	19K	19K	19K	18K
Retained Earnings	288.07M	329.5M	306.15M	382.79M	344.64M	391.64M	445.22M	478.94M	465.72M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.43M	-10.39M	-13.9M	-3.63M	458K	-12.79M	-13.7M	-22.67M	-16.18M
Minority Interest	0	0	0	0	0	0	0	54.22M	53.17M

USNA Cash Flow Statement

USANA Health Sciences, Inc. (USNA) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Jan'26
Cash from Operations	123.78M	152.12M	126.73M	160.4M	121.23M	103.9M	70.64M	60.99M	22.35M
Operating CF Margin %	11.82%	12.79%	11.95%	14.14%	10.22%	10.4%	7.67%	7.14%	2.42%
Operating CF Growth %	-9.67%	22.89%	-16.69%	26.57%	-24.42%	-14.29%	-32.01%	-13.66%	-63.36%
Net Income	62.53M	126.22M	100.53M	124.66M	116.5M	69.35M	63.79M	42.06M	10.76M
Depreciation & Amortization	16.11M	16.84M	23.01M	22.51M	22.19M	21.41M	20.39M	22.23M	32.56M
Stock-Based Compensation	15.48M	14.96M	15.54M	14.39M	14.3M	13.48M	14.6M	14.56M	13.83M
Deferred Taxes	19.31M	699K	-3.63M	-2.42M	-2.97M	-7.18M	-2.75M	-6.74M	-7.13M
Other Non-Cash Items	2.75M	1.15M	84K	701K	61K	6.07M	2.61M	1.89M	15.41M
Working Capital Changes	7.6M	-7.75M	-8.79M	556K	-28.86M	771K	-28M	-13M	-43.08M
Change in Receivables	0	0	0	0	0	0	0	0	0
Change in Inventory	6.05M	-23.1M	12.99M	-16.78M	-10.5M	15.8M	2.35M	-2.12M	-34.69M
Change in Payables	3.04M	-1.72M	1.83M	6.08M	-4.57M	-2.66M	-428K	-1.27M	5.2M
Cash from Investing	-12.9M	-69M	47.49M	-33.96M	-14.19M	-12.37M	-11.97M	-213.09M	-10.13M
Capital Expenditures	-13.22M	-11.43M	-16.57M	-15.09M	-12.76M	-10.4M	-14.49M	-10.07M	-13.82M
CapEx % of Revenue	1.26%	0.96%	1.56%	1.33%	1.08%	1.04%	1.57%	1.18%	1.49%
Acquisitions	22K	381K	17K	6K	-1.94M	-6.53M	0	-203.34M	0
Investments	-	-	-	-	-	-	-	-	-
Other Investing	318K	4.85M	231K	281K	131K	7K	15K	64K	3.7M
Cash from Financing	-50.32M	-105.28M	-152.05M	-59.44M	-181.41M	-30.09M	-14.24M	9.55M	-40.6M
Debt Issued (Net)	0	0	-65K	-46K	0	0	792K	22.22M	-9M
Equity Issued (Net)	-50M	-105.38M	-151.99M	-57.03M	-177.84M	-25.38M	-11.6M	-9.44M	-27.51M
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-50M	-105.38M	-150M	-57.03M	-177.84M	-25.38M	-11.6M	-9.44M	-27.51M
Other Financing	-316K	98K	0	-2.37M	-3.58M	-4.71M	-3.43M	-3.22M	-4.1M
Net Change in Cash	71.36M▲ 0%	-33.3M▼ 146.7%	20.45M▲ 161.4%	78.25M▲ 282.6%	-72.28M▼ 192.4%	47.67M▲ 165.9%	41.93M▼ 12.0%	-148.74M▼ 454.8%	-23.27M▲ 84.4%
Free Cash Flow	110.56M▲ 0%	140.69M▲ 27.2%	110.16M▼ 21.7%	145.31M▲ 31.9%	108.46M▼ 25.4%	93.5M▼ 13.8%	56.15M▼ 40.0%	50.92M▼ 9.3%	8.53M▼ 83.3%
FCF Margin %	10.56%	11.83%	10.38%	12.81%	9.14%	9.36%	6.1%	5.96%	0.92%
FCF Growth %	5.97%	27.25%	-21.7%	31.9%	-25.36%	-13.79%	-39.95%	-9.31%	-83.26%
FCF per Share	4.47	5.71	4.83	6.84	5.33	4.84	2.90	2.66	0.46
FCF Conversion (FCF/Net Income)	1.98x	1.21x	1.26x	1.29x	1.04x	1.50x	1.11x	1.45x	2.08x
Interest Paid	16K	6K	11K	711K	10K	49K	68K	76K	0
Taxes Paid	46.01M	70.68M	54.91M	53.02M	59.52M	45.86M	44.25M	40.47M	0

USNA Key Ratios

USANA Health Sciences, Inc. (USNA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	33.01%	18.17%	33.47%	27.06%	31.43%	27.85%	16.72%	13.69%	7.76%	1.84%
Return on Invested Capital (ROIC)	72.41%	74.84%	96.46%	68.68%	90.44%	79.08%	48.56%	41.08%	15.95%	8.61%
Gross Margin	80.75%	81.35%	81.72%	80.96%	80.36%	80.54%	79.24%	79.44%	79.43%	78.29%
Net Margin	9.94%	5.97%	10.61%	9.48%	10.99%	9.82%	6.94%	6.93%	4.92%	1.16%
Debt / Equity	-	-	-	0.07x	0.05x	0.04x	0.03x	0.03x	0.07x	0.02x
Interest Coverage	312.21x	2927.96x	5320.72x	2215.00x	351.98x	2994.72x	566.73x	392.04x	272.71x	50.32x
FCF Conversion	1.37x	1.98x	1.21x	1.26x	1.29x	1.04x	1.50x	1.11x	1.45x	2.08x
Revenue Growth	9.54%	4.09%	13.56%	-10.79%	6.95%	4.57%	-15.83%	-7.77%	-7.22%	8.28%

USNA SEC Filings & Documents

USANA Health Sciences, Inc. (USNA) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 5, 2026·SEC

Material company update

Feb 18, 2026·SEC

Material company update

Jan 12, 2026·SEC

10-K Annual Reports

FY 2026

Mar 16, 2026·SEC

FY 2025

Mar 12, 2025·SEC

10-Q Quarterly Reports

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 5, 2025·SEC

FY 2025

May 6, 2025·SEC

USNA Frequently Asked Questions

USANA Health Sciences, Inc. (USNA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

USANA Health Sciences, Inc. (USNA) reported $925.3M in revenue for fiscal year 2025. This represents a 1532% increase from $56.7M in 1996.

USANA Health Sciences, Inc. (USNA) grew revenue by 8.3% over the past year. This is steady growth.

Yes, USANA Health Sciences, Inc. (USNA) is profitable, generating $10.8M in net income for fiscal year 2025 (1.2% net margin).

Dividend & Returns

USANA Health Sciences, Inc. (USNA) has a return on equity (ROE) of 1.8%. This is below average, suggesting room for improvement.

USANA Health Sciences, Inc. (USNA) generated $8.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More USNA

USANA Health Sciences, Inc. (USNA) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

USANA Health Sciences, Inc.(USNA)Earnings, Financials & Key Ratios

USNA Key Insights

✓Strengths

✗Weaknesses

USNA Price & Volume

USNA Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

USNA Recent Earnings

USNA Peer Comparison

Compare USNA vs Peers

vs NUS

vs AMZN

Compare Top 5

USNA Income Statement

USNA Balance Sheet

USNA Cash Flow Statement

USNA Key Ratios

USNA SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

USNA Frequently Asked Questions

Explore More USNA

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation